UTP20 small subunit processome componentGenealiases: 1A6/DRIM · DRIM
Q-omics provides the consensus-scored UTP20 profile across patient tissues and cancer cell-line models. UTP20 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, UTP20 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, UTP20 protein abundance shows 28,300 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRP, and LSCC as cancer lineages where UTP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UTP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UTP20 survival associations across molecular data types. UTP20 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UTP20 RNA expression–survival associations across cancer types. High UTP20 expression shows unfavorable associations in MESO, LIHC, LGG and BLCA, but favorable associations in KIRC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for UTP20 RNA expression.
This table summarizes UTP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UTP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UTP20 shows higher tumor expression in KIRP, KIRC, KICH, LIHC, COAD and BLCA. The KIRP box plot shows higher UTP20 RNA expression in tumor versus normal tissue (log2 FC = +1.094, t-test p < 0.001).
This table shows molecular features associated with UTP20 in patient tissues and cancer cell lines. In patient samples, UTP20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UTP20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
